A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine
Sijie Wang1, Aktan Alpsoy1,2, Surbhi Sood1,2
1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, College of Pharmacy, 201 S. University St., West Lafayette, IN, 47907, USA.
Summary
Researchers developed a selective probe, SW2_152F, targeting CBX2 chromodomain (ChD) in prostate cancer. This probe inhibits CBX2 chromatin binding and blocks cancer cell differentiation, offering a new therapeutic strategy.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- Polycomb group (PcG) proteins are crucial epigenetic regulators in development and cancer.
- PRC1 and PRC2 complexes modify chromatin, with PRC2 marking H3K27me3, recognized by CBX subunits.
- CBX2 is overexpressed in cancers, especially advanced prostate cancer, making it a therapeutic target.
Purpose of the Study:
- To discover a selective inhibitor for the CBX2 chromodomain (ChD) to target prostate cancer.
- To overcome challenges in developing selective CBX inhibitors due to high structural similarity among CBX paralogs.
Main Methods:
- Utilized DNA-encoded libraries (DELs) for focused screening.
- Discovered and characterized the selective CBX2 ChD probe, SW2_152F.
- Assessed probe's binding affinity, selectivity, cell permeability, and functional effects in prostate cancer cells.
Main Results:
- Identified SW2_152F with an 80 nM Kd for CBX2 ChD.
- Demonstrated 24-1000-fold selectivity for CBX2 ChD over other CBX paralogs in vitro.
- Confirmed SW2_152F is cell-permeable, inhibits CBX2 chromatin binding, and blocks prostate cancer neuroendocrine differentiation.
Conclusions:
- SW2_152F is a potent and selective chemical probe for CBX2.
- This probe effectively inhibits CBX2 function in prostate cancer cells.
- SW2_152F shows potential for developing targeted therapies against prostate cancer.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:34Inhibition of Cdk Activity
5.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.6K